NCT05410717 is a phase1/2, open-label, single-arm trial investigating the safety and feasibility of Claudin 6 (CLDN6) targeting autologous CAR-NK cells in patients with CLDN6-expressing advanced solid tumors, including ovarian and testicular cancers [40]. This evidence concerns the gene CLDN6 and testicular cancer.